Prof. PeptideProf. Peptide

November 16, 2026

COURAGE Trial: A Myostatin Antibody Preserved Lean Mass on Semaglutide

Weight loss on semaglutide takes muscle with it. In COURAGE, a phase 2 trial published in The Lancet on November 11, 2026, adding trevogrumab, an investigational antibody that blocks myostatin, reduced that lean-mass loss in adults with obesity. Adding a second antibody, garetosmab, kept more lean mass still, but the combination brought frequent serious adverse events and discontinuations, and two deaths. The trial was funded by Regeneron Pharmaceuticals.

About these figures. Every figure is from the paper’s published abstract (Mosenzon O, Rosenstock J, et al.), which is peer-reviewed. Lean mass and fat mass are body-composition measures; the trial’s primary end points did not include strength or physical function.

What COURAGE tested

Myostatin (GDF8) and activin A are signals that hold muscle growth in check. COURAGE (ClinicalTrials.gov NCT06299098) was a two-part, double-blind, placebo-controlled trial at 60 US sites in adults aged 18 to 80 with a body-mass index of at least 30. Everyone received semaglutide, titrated to 2.4 mg once weekly. 975 participants were enrolled between June 2024 and April 2025; mean age was 49 and 64% were women.

  • Part A, 26 weeks (605 participants): semaglutide plus placebo, trevogrumab 200 mg or 400 mg by weekly subcutaneous injection, or trevogrumab 400 mg plus garetosmab 10 mg/kg intravenously every 4 weeks.
  • Part B, 52 weeks (376 participants): semaglutide plus placebo, trevogrumab 25 mg or trevogrumab 75 mg.

The primary end points were the percentage change in lean mass, fat mass and body weight.

Lean mass

  • Part A, week 26. Lean mass fell 6.6% with semaglutide plus placebo. Against that, the estimated treatment difference was +3.1 percentage points with trevogrumab 200 mg (95% CI 1.9 to 4.3), +2.7 with 400 mg (1.5 to 4.0) and +4.5 with 400 mg plus garetosmab (3.1 to 5.9).
  • Part B, week 52. Lean mass fell 7.3% with semaglutide plus placebo. The difference was +1.5 with trevogrumab 25 mg (−0.3 to 3.3, not significant) and +3.1 with 75 mg (1.3 to 4.9).

Fat mass and body weight

Fat mass fell 15.6% with semaglutide plus placebo in part A. Only two groups lost significantly more: trevogrumab 400 mg (−3.4 percentage points) and trevogrumab 400 mg plus garetosmab (−11.7). Body weight fell 10.6% with semaglutide plus placebo, and only the combination lost significantly more (−2.7 percentage points). No part B group differed from semaglutide plus placebo on fat mass or body weight.

Safety: the combination arm

The authors describe trevogrumab alone, at 25 to 400 mg, as “generally well tolerated with a safety profile similar to semaglutide plus placebo.” The combination with garetosmab was different:

  • Serious adverse events in 14 of 149 participants (9%), and treatment discontinuation in 48 of 149 (32%).
  • Muscle spasms in 61 of 149 (41%), against 23 of 299 (8%) with trevogrumab 200 or 400 mg and 7 of 151 (5%) with semaglutide plus placebo.
  • Two deaths, both in the combination group; the authors write that “a causal association between treatment and these events was not identified.”

Gastrointestinal adverse events were the most common across all groups, at similar rates, and most adverse events were mild to moderate. The authors conclude that the study “establishes proof of concept” for trevogrumab alone, that the combination “did not have favourable safety and tolerability,” and that “further study is required” to learn whether better body composition preserves physical function and metabolic health.

Is this the same as follistatin?

No. Trevogrumab is an investigational antibody tested in clinical trials; it is not sold. Myostatin blocking is also the rationale behind follistatin, a different molecule sold as research-grade material, but COURAGE did not test follistatin, and its results do not show that follistatin vials do the same.

What this is, and isn’t

Neither trevogrumab nor garetosmab is approved anywhere, and these results do not make either available. COURAGE measured body composition, not strength or how people function day to day, and its trevogrumab-alone results are phase 2 proof of concept.

Sources

This article is for informational and educational purposes only and does not constitute medical advice, a dosing recommendation or a usage recommendation.

Checked and updated